Clermont-Ferrand University Hospital (CHU) is opening MoSIRIS, a new day hospital dedicated to preventing medication-related iatrogenic risks, located at the Gabriel-Montpied site.
Latrogenic risk refers to adverse events related to medical care, and more specifically those associated with the use of medications. It can result from inappropriate prescribing, drug–drug interactions, treatment accumulation, or a mismatch between therapies and the patient’s clinical condition. This risk is increased in complex situations, particularly among patients taking multiple medications, those with several chronic conditions, and individuals who are frail or elderly. Preventing this risk is now a major public health challenge.
A day hospital to prevent medication-related iatrogenesis.
MoSIRIS positions itself as an innovative program dedicated to ensuring the safety and appropriateness of medication management. Within a half day, without full hospitalization, patients benefit from a comprehensive and coordinated assessment of their therapeutic regimen and overall health status. The objective is to identify high‑risk situations, optimize treatments when necessary, ensure their relevance in light of the patient’s clinical condition and care goals, and prevent avoidable medication‑related adverse events, with a focus on improving quality of life and maintaining autonomy.
Led by a multidisciplinary team, MoSIRIS is part of a model of strengthened coordination between the hospital and community‑based healthcare professionals. Each visit results in a clear and practical summary, provided to the patient and then shared with their general practitioner and pharmacist, ensuring continuity of care and truly integrated management.
A program open to patients most at risk.
The program is primarily intended for patients experiencing polypharmacy, receiving complex or high‑risk treatments, presenting with frailty or difficulties in managing their medication, or requiring a therapeutic reassessment following hospitalization.
Referral may be made by a hospital physician, a private practitioner, or a community pharmacist, particularly when iatrogenic risk is identified during a consultation or hospitalization.
A commitment to quality and safety of care.
By strengthening coordination between hospital and community-based care, MoSIRIS contributes to a safer, more appropriate, and better-coordinated care pathway. The program helps reduce preventable adverse events and improve the safety of prescriptions, to the direct benefit of patients.
